Skip to content
All Sections
Subscribe Now
69°F
Tuesday, July 23rd 2024
e-Edition
Home Page
Close Menu
News
News
Crime and Public Safety
Investigative Reporting
Politics
Health
Environment
Business
Best Reviews
Housing
Jobs
Local News
Local News
Long Beach
Los Angeles
Los Angeles County
Sports
Sports
High School Sports
Chargers
Rams
Lakers
Clippers
Dodgers
Angels
College Sports
UCLA Sports
USC Sports
Long Beach State sports
Kings
Ducks
Olympics
Boxing/MMA
Soccer
Horse Racing
Things To Do
Things To Do
Restaurants Food and Drink
Movies
Music + Concerts
Theater
TV and Streaming
Home + Garden
Travel
Amusement Parks
Comics
Puzzles
Events
Obituaries
Obituaries
News Obituaries
Place an Obituary
Opinion
Opinion
Editorials
Opinion Columns
Commentary
Letters to the Editor
Editorial Board
Endorsements
The Grunion
The Grunion
News
Education
Sports
Things to Do
Opinion
E-Edition
Advertising
Contact Us
SCNG Premium
The T.E.A.
Subscribe
Press-Telegram Store
Log In
Logout
Close Menu
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Account Settings
Contact Us
Log Out
Spoof a user
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Search
Press Telegram
69°F
Tuesday, July 23rd 2024
e-Edition
News
Local News
Sports
Things to Do
Obituaries
Opinion
The T.E.A.
Trending:
Biden drops out of race
Project 2025's impact in CA
Homeless pet food pantry opens
SpaceX moving to Texas
LB Burger Week ð
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Aurinia Pharmaceuticals Inc.
< Previous
1
2
3
Next >
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024
July 19, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia to Participate in Upcoming Investor Healthcare Conferences
July 02, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Announces 2024 Annual General Meeting Results
June 14, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
June 05, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
June 04, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Provides Update on Proxy Statement
June 03, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
May 30, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
May 14, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
May 09, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
May 07, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
May 02, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
May 01, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
April 30, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
April 16, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
April 15, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
April 09, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
February 29, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia to Participate in Upcoming Investor Healthcare Conferences
February 27, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
February 15, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024
February 05, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results
January 05, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Submits IND Application to US Food & Drug Administration for AUR 200
December 20, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan
November 13, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023
November 07, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis
November 02, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
November 02, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis
October 26, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023
October 19, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)
October 13, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital
September 21, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close